

APPLIED DNA SCIENCES INC  
 Form 4  
 July 01, 2015

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Hayward James A

2. Issuer Name and Ticker or Trading Symbol  
 APPLIED DNA SCIENCES INC [APDN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 50 HEALTH SCIENCES DRIVE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 06/30/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chairman, CEO and President

STONY BROOK, NY 11790

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Code V Amount (D) Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities Acquired (A) or	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Underlying (Instr. 3 and
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	--	--	---------------------------------------

**Edgar Filing: APPLIED DNA SCIENCES INC - Form 4**

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8) Code	Disposed of (D) (Instr. 3, 4, and 5)	(A)	(D)	Date Exercisable	Expiration Date	Title
Employee Stock Option (right to buy)	\$ 3.6	06/30/2015	D <sup>(1)</sup>			166,667	<u>(1)</u>	06/30/2015 <sup>(1)</sup>	Common Stock
Employee Stock Option (right to buy)	\$ 3.6	06/30/2015	A <sup>(1)</sup>		166,667		06/30/2015	06/30/2020 <sup>(1)</sup>	Common Stock

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hayward James A 50 HEALTH SCIENCES DRIVE STONY BROOK, NY 11790	X	X	Chairman, CEO and President	

**Signatures**

/s/ Beth Jantzen,  
Attorney-in-Fact  
07/01/2015

          Signature of Reporting Person    Date

**Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The two reported transactions involve an amendment of an outstanding option to extend the expiration date of such option from June 30, 2015 to June 30, 2020, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was (1) originally granted on July 1, 2010 and provided for vesting (i) with respect to 25% of the underlying shares on the original date of grant and (ii) with respect to the remaining underlying shares, ratably each anniversary thereafter until fully vested on the third anniversary of the original date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.